Brainsway (BWAY) CEO discloses share ownership and stock options
Rhea-AI Filing Summary
Brainsway Ltd. filed a Form 3 showing the initial equity holdings of Chief Executive Officer Levy Hadar. The filing reports direct ownership of 123,050 Ordinary Shares, which includes 16,800 shares and unvested restricted stock units that convert into shares as they vest.
Hadar also holds stock options over 80,000 Ordinary Shares granted on February 9, 2023 with an exercise price of NIS 3.65 per share, vesting in equal quarterly installments until February 13, 2027. Additional options cover 62,500 Ordinary Shares granted on March 5, 2024 at an exercise price of NIS 11.17 per share, vesting in equal quarterly installments until March 5, 2028.
Positive
- None.
Negative
- None.
Insights
Form 3 outlines CEO’s existing equity stake and option grants, without new buy or sell activity.
The Form 3 for Brainsway Ltd. details Chief Executive Officer Levy Hadar’s baseline ownership rather than new transactions. It lists 123,050 directly held Ordinary Shares, including unvested RSUs that will convert into shares over time if vesting conditions are met.
The filing also shows two significant option packages: 80,000 shares at an exercise price of NIS 3.65 expiring in 2033, and 62,500 shares at NIS 11.17 expiring in 2034, both vesting quarterly over several years. This structure ties a meaningful portion of compensation to long-term company performance, but does not itself signal any immediate bullish or bearish trading activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options (right to buy) | -- | -- | -- |
| holding | Stock Options (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. This figure includes: (i) 16,800 ordinary shares and (ii) unvested restricted stock units ("RSUs"), with each RSU representing a contingent right to receive one ordinary share, as follows: (a) RSUs to receive 31,250 ordinary shares vesting in equal quarterly installments until March 5, 2028 and (b) RSUs to receive 75,000 ordinary shares vesting in equal yearly installments until March 9, 2029, subject to certain vesting conditions. Stock options were granted on February 9, 2023, with the remaining options to purchase 80,000 ordinary shares vesting in equal quarterly installments until February 13, 2027, with acceleration in the event of a change of control. The exercise price is NIS 3.65 per share. Stock options were granted on March 5, 2024, with the remaining options to purchase 62,500 ordinary shares vesting in equal quarterly installments until March 5, 2028. The exercise price is NIS 11.17 per share.
